-
2
-
-
42449114035
-
Multiple myeloma
-
Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111: 2962-72.
-
(2008)
Blood
, vol.111
, pp. 2962-2972
-
-
Kyle, R.A.1
Rajkumar, S.V.2
-
3
-
-
85027950818
-
Update on risk stratification and treatment of newly diagnosed multiple myeloma
-
Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol. 2011;94(4):310-20.
-
(2011)
Int J Hematol
, vol.94
, Issue.4
, pp. 310-320
-
-
Kapoor, P.1
Rajkumar, S.V.2
-
4
-
-
0026786675
-
Evidence that multiple myeloma ig heavy chain vdj genes contain somatic mutations but show no intraclonal variation
-
Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood. 1992;80:2326-35.
-
(1992)
Blood
, vol.80
, pp. 2326-2335
-
-
Bakkus, M.H.1
Heirman, C.2
Van Riet, I.3
Van Camp, B.4
Thielemans, K.5
-
5
-
-
0029077309
-
Myeloma ig heavy chain v region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity
-
Vescio RA, Cao J, Hong CH, et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol. 1995; 155:2487-97.
-
(1995)
J Immunol
, vol.155
, pp. 2487-2497
-
-
Vescio, R.A.1
Cao, J.2
Hong, C.H.3
-
6
-
-
0030614775
-
Myeloma Vl and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells
-
Sahota SS, Leo R, Hamblin TJ, Stevenson FK. Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells. Blood. 1997;89:219-26.
-
(1997)
Blood
, vol.89
, pp. 219-226
-
-
Sahota, S.S.1
Leo, R.2
Hamblin, T.J.3
Stevenson, F.K.4
-
7
-
-
0026552179
-
Monoclonal circulating b cells in multiple myeloma, A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules
-
Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am. 1992;6:297-322.
-
(1992)
Hematol Oncol Clin North Am
, vol.6
, pp. 297-322
-
-
Pilarski, L.M.1
Jensen, G.S.2
-
8
-
-
0028908877
-
In multiple myeloma, clonotypic b lymphocytes are detectable among CD19? Peripheral blood cells expressing CD38, CD56, and monotypic ig light chain
-
Bergsagel PL, Smith AM, Szczepek A, Mant MJ, Belch AR, Pilarski LM. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19? peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood. 1995;85:436-47.
-
(1995)
Blood
, vol.85
, pp. 436-447
-
-
Bergsagel, P.L.1
Smith, A.M.2
Szczepek, A.3
Mant, M.J.4
Belch, A.R.5
Pilarski, L.M.6
-
9
-
-
0030049654
-
Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of b cells
-
Chen BJ, Epstein J. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood. 1996;87: 1972-6.
-
(1996)
Blood
, vol.87
, pp. 1972-1976
-
-
Chen, B.J.1
Epstein, J.2
-
10
-
-
0036240724
-
The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatment
-
Rasmussen T, Jensen L, Johnsen HE. The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatment. Leuk Lymphoma. 2002;43:1075-7.
-
(2002)
Leuk Lymphoma
, vol.43
, pp. 1075-1077
-
-
Rasmussen, T.1
Jensen, L.2
Johnsen, H.E.3
-
11
-
-
0036191321
-
Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice
-
Pilarski LM, Seeberger K, Coupland RW, et al. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol. 2002;30:221-8.
-
(2002)
Exp Hematol
, vol.30
, pp. 221-228
-
-
Pilarski, L.M.1
Seeberger, K.2
Coupland, R.W.3
-
12
-
-
0034142369
-
Myeloma progenitors in the blood of patients with aggressive or minimal disease: Engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice
-
Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood. 2000;95:1056-65.
-
(2000)
Blood
, vol.95
, pp. 1056-1065
-
-
Pilarski, L.M.1
Hipperson, G.2
Seeberger, K.3
Pruski, E.4
Coupland, R.W.5
Belch, A.R.6
-
13
-
-
1542283717
-
Characterization of clonogenic multiple myeloma cells
-
Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103:2332-6.
-
(2004)
Blood
, vol.103
, pp. 2332-2336
-
-
Matsui, W.1
Huff, C.A.2
Wang, Q.3
-
14
-
-
38549132452
-
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
-
Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68:190-7.
-
(2008)
Cancer Res
, vol.68
, pp. 190-197
-
-
Matsui, W.1
Wang, Q.2
Barber, J.P.3
-
15
-
-
40949138516
-
Anti-CD20 monoclonal antibody therapy in multiple myeloma
-
Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol. 2008;141:135-48.
-
(2008)
Br J Haematol
, vol.141
, pp. 135-148
-
-
Kapoor, P.1
Greipp, P.T.2
Morice, W.G.3
Rajkumar, S.V.4
Witzig, T.E.5
Greipp, P.R.6
-
16
-
-
84865862858
-
CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients
-
Hosen N, Matsuoka Y, Kishida S, et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia. 2012;26:2135-41.
-
(2012)
Leukemia
, vol.26
, pp. 2135-2141
-
-
Hosen, N.1
Matsuoka, Y.2
Kishida, S.3
-
17
-
-
84871238560
-
CD19(-)CD45(low/-)CD38(high)/CD138 plasma cells enrich for human tumorigenic myeloma cells
-
Kim D, Park CY, Medeiros BC, Weissman IL. CD19(- )CD45(low/-)CD38(high)/ CD138 plasma cells enrich for human tumorigenic myeloma cells. Leukemia. 2012;26(12):2530-7.
-
(2012)
Leukemia
, vol.26
, Issue.12
, pp. 2530-2537
-
-
Kim, D.1
Park, C.Y.2
Medeiros, B.C.3
Weissman, I.L.4
-
18
-
-
0032532608
-
Primary myeloma cells growing in SCID-HU mice: A model for studying the biology and treatment of myeloma and its manifestations
-
Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92:2908-13.
-
(1998)
Blood
, vol.92
, pp. 2908-2913
-
-
Yaccoby, S.1
Barlogie, B.2
Epstein, J.3
-
19
-
-
8844264524
-
The SCID-RAB model: A novel in vivo system for primary human myeloma demonstrating growth of CD138- expressing malignant cells
-
Yata K, Yaccoby S. The SCID-rab model: A novel in vivo system for primary human myeloma demonstrating growth of CD138- expressing malignant cells. Leukemia. 2004;18:1891-7.
-
(2004)
Leukemia
, vol.18
, pp. 1891-1897
-
-
Yata, K.1
Yaccoby, S.2
-
20
-
-
84865011312
-
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
-
Kawano Y, Fujiwara S, Wada N, et al. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int J Oncol. 2012;41(3):876-84.
-
(2012)
Int J Oncol
, vol.41
, Issue.3
, pp. 876-884
-
-
Kawano, Y.1
Fujiwara, S.2
Wada, N.3
-
21
-
-
77953229444
-
Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells
-
Fuhler GM, Baanstra M, Chesik D, et al. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res. 2010;316: 1816-28.
-
(2010)
Exp Cell Res
, vol.316
, pp. 1816-1828
-
-
Fuhler, G.M.1
Baanstra, M.2
Chesik, D.3
-
22
-
-
79955974540
-
Lenalidomide targets clonogenic side population in multiple myeloma: Pathophysiologic and clinical implications
-
Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011;117:4409-19.
-
(2011)
Blood
, vol.117
, pp. 4409-4419
-
-
Jakubikova, J.1
Adamia, S.2
Kost-Alimova, M.3
-
23
-
-
34547106018
-
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
-
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585-98.
-
(2007)
Nat Rev Cancer
, vol.7
, Issue.8
, pp. 585-598
-
-
Hideshima, T.1
Mitsiades, C.2
Tonon, G.3
Richardson, P.G.4
Anderson, K.C.5
-
24
-
-
85027940706
-
Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma
-
Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol. 2011;94(4):334-43.
-
(2011)
Int J Hematol
, vol.94
, Issue.4
, pp. 334-343
-
-
Abe, M.1
-
25
-
-
84856693203
-
Neovascular niche for human myeloma cells in immunodeficient mouse bone
-
Iriuchishima H, Takubo K, Miyakawa Y, et al. Neovascular niche for human myeloma cells in immunodeficient mouse bone. PLoS One. 2012;7(2):e30557.
-
(2012)
PLoS One
, vol.7
, Issue.2
-
-
Iriuchishima, H.1
Takubo, K.2
Miyakawa, Y.3
-
26
-
-
70349836514
-
Niche regulation of hematopoietic stem cells in the endosteum
-
Arai F, Yoshihara H, Hosokawa K, et al. Niche regulation of hematopoietic stem cells in the endosteum. Ann N Y Acad Sci. 2009;1176:36-46.
-
(2009)
Ann N Y Acad Sci
, vol.1176
, pp. 36-46
-
-
Arai, F.1
Yoshihara, H.2
Hosokawa, K.3
-
27
-
-
80051589767
-
Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia
-
Kikushige Y, Ishikawa F, Miyamoto T, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 2011;20(2):246-59.
-
(2011)
Cancer Cell
, vol.20
, Issue.2
, pp. 246-259
-
-
Kikushige, Y.1
Ishikawa, F.2
Miyamoto, T.3
-
28
-
-
34247192972
-
Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma
-
Peacock CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA. 2007;104:4048-53.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 4048-4053
-
-
Peacock, C.D.1
Wang, Q.2
Gesell, G.S.3
-
29
-
-
41349095228
-
Inhibition of notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy
-
Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2008;111: 2220-9.
-
(2008)
Blood
, vol.111
, pp. 2220-2229
-
-
Nefedova, Y.1
Sullivan, D.M.2
Bolick, S.C.3
Dalton, W.S.4
Gabrilovich, D.I.5
-
30
-
-
85027944452
-
Novel therapies in MM: From the aspect of preclinical studies
-
Hideshima T, Anderson KC. Novel therapies in MM: from the aspect of preclinical studies. Int J Hematol. 2011;94(4):344-54.
-
(2011)
Int J Hematol
, vol.94
, Issue.4
, pp. 344-354
-
-
Hideshima, T.1
Anderson, K.C.2
-
31
-
-
84863922801
-
CS1-directed monoclonal antibody therapy for multiple myeloma
-
Benson DM Jr, Byrd JC. CS1-directed monoclonal antibody therapy for multiple myeloma. J Clin Oncol. 2012;30(16): 2013-5.
-
(2012)
J Clin Oncol
, vol.30
, Issue.16
, pp. 2013-2015
-
-
Benson Jr., D.M.1
Byrd, J.C.2
-
32
-
-
79251570884
-
Daratumumab, A novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
-
de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-8.
-
(2011)
J Immunol
, vol.186
, Issue.3
, pp. 1840-1848
-
-
De Weers, M.1
Tai, Y.T.2
Van Der Veer, M.S.3
-
33
-
-
84155195009
-
CD48 as a novel molecular target for antibody therapy in multiple myeloma
-
Hosen N, Ichihara H, Mugitani A, et al. CD48 as a novel molecular target for antibody therapy in multiple myeloma. Br J Haematol. 2011;156:213-24.
-
(2011)
Br J Haematol
, vol.156
, pp. 213-224
-
-
Hosen, N.1
Ichihara, H.2
Mugitani, A.3
|